What is Alebund Pharmaceuticals?
Alebund Pharmaceuticals operates as a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of novel therapies. Its primary focus lies in the treatment of kidney diseases and their associated complications, alongside a broader commitment to addressing various chronic health conditions. By leveraging a science-driven research model, the company bridges the gap between laboratory-based discovery and clinical application, positioning itself as a critical player in the global biotech landscape. The firm's operational strategy emphasizes the development of high-efficacy treatments that address significant unmet medical needs, thereby enhancing its competitive standing within the pharmaceutical industry.
How much funding has Alebund Pharmaceuticals raised?
Alebund Pharmaceuticals has raised a total of $184.6M across 3 funding rounds:
Series B
$60M
Other Financing Round
$54.5M
Series C
$70.1M
Series B (2021): $60M with participation from Med-Fine Capital, 3E Bioventures Capital, Sherpa Healthcare Partners, Quan Capital, and Lilly Asia Ventures
Other Financing Round (2021): $54.5M led by Loyal Valley Capital, Morningside Ventures, YuanBio Venture Capital, and 3H Health Investment
Series C (2025): $70.1M, investors not publicly disclosed
Key Investors in Alebund Pharmaceuticals
Loyal Valley Capital
Loyal Valley Capital is a research-oriented private equity firm that acts as a strategic partner for high-growth companies, leveraging deep industry expertise to support market leaders.
3E Bioventures Capital
3E Bioventures Capital is a science-driven investment firm with a global footprint, focusing on drug development and products that address significant unmet medical needs through expertise and execution.
Lilly Asia Ventures
Lilly Asia Ventures is a premier biomedical venture capital firm that provides smart capital to exceptional entrepreneurs, aiming to build companies that develop breakthrough products for human health.
What's next for Alebund Pharmaceuticals?
With the successful closure of its latest financing round, Alebund Pharmaceuticals is well-positioned to accelerate its clinical trial programs and expand its research capabilities. The strategic allocation of this capital will likely focus on advancing lead candidates through late-stage clinical testing and strengthening the company's intellectual property portfolio. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward regulatory milestones and potential commercialization pathways. Investors will be closely monitoring the company's ability to maintain its pace of innovation while navigating the complex regulatory environments inherent in the development of breakthrough therapies for chronic diseases.
See full Alebund Pharmaceuticals company page
